Literature DB >> 27358244

Metastatic pancreatic adenocarcinoma associated with chronic calcific pancreatitis and a heterozygous SPINK1 N34S mutation.

Robert A Moran1, Robert Klapheke2, Niloofar Y Jalaly3, Martin A Makary4, Kenzo Hirose4, Michael Goggins5, Laura Wood6, Daniel A Laheru7, Anne Marie Lennon3, Mouen A Khashab3, Vikesh K Singh8.   

Abstract

Contrary to patients with a cationic trypsinogen gene (PRSS1) mutations, Serine protease inhibitor Kazal-type 1 (SPINK1) heterozygote gene mutation carriers have a very low penetrance for acute, acute recurrent and/or chronic pancreatitis. Despite this, heterozygote SPINK 1 gene mutation patients have a similar age of onset of pancreatitis as PRSS 1 gene mutation patients. While the substantially elevated risk of pancreatic cancer in patients with PRSS1 gene mutations with chronic pancreatitis has been well established, little is known about the risk of pancreatic cancer in SPINK 1 gene mutation carriers with pancreatitis. We describe a case of malignant pancreatic cancer diagnosed in a young patient with chronic pancreatitis who is a SPINK 1 heterozygote gene mutation carrier. The risk of pancreatic cancer in gene mutation patients with chronic pancreatitis, in addition to screening options and management options for these patients is discussed.
Copyright © 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic pancreatitis; Pancreatic adenocarcinoma; SPINK1

Mesh:

Substances:

Year:  2016        PMID: 27358244     DOI: 10.1016/j.pan.2016.06.006

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  2 in total

1.  High Prevalence of Serine Protease Inhibitor Kazal Type 1 Gene Variations Detected by Whole Gene Sequencing in Patients with Fibrocalculous Pancreatic Diabetes.

Authors:  Anish Kolly; C Shivaprasad; Annie A Pulikkal; Sridevi Atluri; Vijaya Sarathi; C S Dwarakanath
Journal:  Indian J Endocrinol Metab       Date:  2017 Jul-Aug

2.  Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance.

Authors:  Fei Chen; Qilai Long; Da Fu; Dexiang Zhu; Yan Ji; Liu Han; Boyi Zhang; Qixia Xu; Bingjie Liu; Yan Li; Shanshan Wu; Chen Yang; Min Qian; Jianmin Xu; Suling Liu; Liu Cao; Y Eugene Chin; Eric W-F Lam; Jean-Philippe Coppé; Yu Sun
Journal:  Nat Commun       Date:  2018-10-17       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.